Literature DB >> 2180549

Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder.

J Bradwejn1, D Koszycki, G Meterissian.   

Abstract

Cholecystokinin-tetrapeptide (CCK-4) and placebo were injected to 11 panic disorder patients. CCK-4 induced a panic attack identical to spontaneous panic attacks in all patients; placebo did not induce any attacks. The role of CCK-4 in anxiety disorders is discussed.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2180549     DOI： 10.1177/070674379003500115

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN： 0706-7437            Impact factor:   4.356


  35 in total

1.  Requirement of phospholipase C and protein kinase C in cholecystokinin-mediated facilitation of NMDA channel function and anxiety-like behavior.

Authors:  Zhaoyang Xiao; Manoj K Jaiswal; Pan-Yue Deng; Toshimitsu Matsui; Hee-Sup Shin; James E Porter; Saobo Lei
Journal:  Hippocampus       Date:  2011-11-10       Impact factor: 3.899

2.  Of monkeys and men: vervets and the genetics of human-like behaviors.

Authors:  R M Palmour; J Mulligan; J J Howbert; F Ervin
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

3.  Enhanced cortical extracellular levels of cholecystokinin-like material in a model of anticipation of social defeat in the rat.

Authors:  C Becker; M H Thièbot; Y Touitou; M Hamon; F Cesselin; J J Benoliel
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

4.  Pentagastrin has panic-inducing properties in obsessive compulsive disorder.

Authors:  A S de Leeuw; J A Den Boer; B R Slaap; H G Westenberg
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

5.  The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist.

Authors:  L Singh; M J Field; J Hughes; R Menzies; R J Oles; C A Vass; G N Woodruff
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

6.  The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze.

Authors:  P Chopin; M Briley
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze.

Authors:  E Vasar; E Peuranen; T Oöpik; J Harro; P T Männistö
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Social isolation of rats increases the density of cholecystokinin receptors in the frontal cortex and abolishes the anti-exploratory effect of caerulein.

Authors:  E Vasar; E Peuranen; J Harro; A Lang; L Oreland; P T Männistö
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

9.  Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.

Authors:  J Shlik; E Vasar; J Bradwejn
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

10.  Interaction between the cholecystokinin and endogenous cannabinoid systems in cued fear expression and extinction retention.

Authors:  Mallory E Bowers; Kerry J Ressler
Journal:  Neuropsychopharmacology       Date:  2014-09-01       Impact factor: 7.853
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.